Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma

Overview of attention for article published in BMC Cancer, September 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 3 tweeters

Readers on

mendeley: 11 Mendeley

Summary Twitter

So far, Altmetric has seen 3 tweets from 3 users, with an upper bound of 3,663 followers.

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma https://t.co/eObEkIQCJL

14 Sep 2022

Reply Retweet Favourite

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma #lymphoma #lymsm https://t.co/S329huedo0

11 Sep 2022

Reply Retweet Favourite

New article: Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma https://t.co/g9msQ5WjBo #DLBCL #lymsm #hematology https://t.co/1dcKPIzml6

11 Sep 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity.